Researchers succumbed to political and media pressure in flocking to study hydroxychloroquine, undercutting resources to pursue potentially more effective Covid-19 drugs in the process, according to a study published Thursday.
The research letter, published in the medical journal JAMA Network Open, adds to the scientific literature that many low-value studies early in the pandemic failed to generate meaningful evidence to help health-care workers treat patients. The Food and Drug Administration estimates about 6% of the Covid-19 studies on ClinicalTrials.gov have actionable results.
The research letter, or short paper, found the number of studies testing hydroxychloroquine, the antimalarial drug touted ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.